Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1840 vs standard of care in pediatric Wilson disease
jRCT2011210038Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
01
Overview
Randomised, open-label trial in Wilson disease (WD) comparing ALXN1840 with Standard of care (2 arms). Primary endpoint: Percentage change in non-ceruloplasmin-bound copper (NCC) in plasma at Week 48. Started Oct 2021; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on jRCT2011210038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210038.